No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life

por Plomgaard, Anne M., Alderliesten, Thomas, van Bel, Frank, Benders, Manon, Claris, Olivier, Cordeiro, Malaika, Dempsey, Eugene, Fumagalli, Monica, Gluud, Christian, Hyttel‐Sorensen, Simon, Lemmers, Petra, Pellicer, Adelina, Pichler, Gerhard, Greisen, Gorm
Publicado 2018

Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: cranial ultrasound and magnetic resonance imaging assessments

por Plomgaard, Anne M, Hagmann, Cornelia, Alderliesten, Thomas, Austin, Topun, van Bel, Frank, Claris, Olivier, Dempsey, Eugene, Franz, Axel, Fumagalli, Monica, Gluud, Christian, Greisen, Gorm, Hyttel-Sorensen, Simon, Lemmers, Petra, Pellicer, Adelina, Pichler, Gerhard, Benders, Manon
Publicado 2016

Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial

por Plomgaard, Anne M., Alderliesten, Thomas, Austin, Topun, van Bel, Frank, Benders, Manon, Claris, Olivier, Dempsey, Eugene, Fumagalli, Monica, Gluud, Christian, Hagmann, Cornelia, Hyttel-Sorensen, Simon, Lemmers, Petra, van Oeveren, Wim, Pellicer, Adelina, Petersen, Tue H., Pichler, Gerhard, Winkel, Per, Greisen, Gorm
Publicado 2017

The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury

por Plomgaard, Anne M., van Oeveren, Wim, Petersen, Tue H., Alderliesten, Thomas, Austin, Topun, van Bel, Frank, Benders, Manon, Claris, Olivier, Dempsey, Eugene, Franz, Axel, Fumagalli, Monica, Gluud, Christian, Hagmann, Cornelia, Hyttel-Sorensen, Simon, Lemmers, Petra, Pellicer, Adelina, Pichler, Gerhard, Winkel, Per, Greisen, Gorm
Publicado 2016